The Top 60: Carbon

CommonHealth's decision to dissolve its professional agency Adient and divide the business between Carbon and Noesis lead to dramatic expansion in 2007, says Darlene Dobry, president. As a result of the merger, Carbon received Ortho-McNeil Pharmaceuticals and Duramed Pharmaceuticals.

Dobry says Ortho-McNeil's Levaquin account was “a lot to take,” in the context of an already growing agency. Joe Maynard, who was attached to Ortho-McNeil at Adient, was taken on as a EVP, managing director. Other “key personnel” also joined Carbon's ranks.

Carbon was responsible for several new launches in 2007, including Ortho-McNeil's Doribax, an anti-infective indicated for complicated intra-abdominal infections and urinary tract infections. The focus on brand launches will continue through 2008 and 2009, says Dobry. “We grew by 50% in 2007. That can partially be attributed to [Adient business], but it also came from new client wins,” she says.

Carbon specializes in anti-infectives, cardiology, women's healthcare and OTC accounts, such as GlaxoSmithKline's weight loss drug Alli. “I'd love to see Carbon expand into [CNS] and diabetes, and other areas where there are unmet needs,” she says.

Dobry credits the CommonHealth network with opportunities to succeed across a diverse climate. “The idea is to create one voice across all media channels.…Many channels and vehicles are required in a launch —it's a multidisciplinary effort,” she says.

In the future, Carbon is “looking to expand across new therapeutic categories, as well as expanding interactive.” 
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.